An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features

Minoru Inomata(Japanese Red Cross Medical Center), Tamiko Takemura, Akihiko Gemma(Nippon Medical School), Yuji Kusunoki(Nippon Medical School), Masahiro Masuo(Japanese Red Cross Medical Center), Noriyo Yanagawa(Tokyo Metropolitan Komagome Hospital), Tsunehiro Ando(Japanese Red Cross Medical Center), Nobuyasu Awano(Japanese Red Cross Medical Center), Arata Azuma(Nippon Medical School Hospital), Kohta Satake(Osaka City University), Hiroyuki Kamiya(Medizinische Hochschule Hannover), Takashi Ogura(Kanagawa Cardiovascular and Respiratory Center), Toshio Kumasaka(Japanese Red Cross Medical Center), Atsuko Moriya(Japanese Red Cross Medical Center), Fumikazu Sakai(Saitama Medical University), Keisuke Kondoh(Japanese Red Cross Medical Center), Soichiro Ikushima(Japanese Red Cross Medical Center)
BMC Pulmonary Medicine
June 28, 2014
10.1186/1471-2466-14-104
Cited by 78

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
|Journal of Clinical Oncology|2009|516